Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helene Karcher

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Ophthalmology|March 29, 2023
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to BrolucizumabMathew W MacCumber, Charles C Wykoff, Helene Karcher, et al.
Retina (Philadelphia, Pa.)|March 9, 2023
RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World EvidenceCharles C Wykoff, Hidetaka Matsumoto, Mark R Barakat, et al.
Pharmacoeconomics|July 25, 2023
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical RecommendationsKumar Mukherjee, Necdet B Gunsoy, Rita M Kristy, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Ophthalmology|March 29, 2023
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to BrolucizumabMathew W MacCumber, Charles C Wykoff, Helene Karcher, et al.
Retina (Philadelphia, Pa.)|March 9, 2023
RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World EvidenceCharles C Wykoff, Hidetaka Matsumoto, Mark R Barakat, et al.
Pharmacoeconomics|July 25, 2023
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical RecommendationsKumar Mukherjee, Necdet B Gunsoy, Rita M Kristy, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
Pageof 4